Reckitt Benckiser Group plc (LON:RKT – Get Free Report) announced a dividend on Thursday, March 6th, DividendData.Co.Uk reports. Investors of record on Thursday, April 10th will be paid a dividend of GBX 121.70 ($1.55) per share on Thursday, May 29th. This represents a yield of 2.38%. The ex-dividend date is Thursday, April 10th. This is a 51.4% increase from Reckitt Benckiser Group’s previous dividend of $80.40. The official announcement can be accessed at this link.
Reckitt Benckiser Group Stock Performance
LON RKT opened at GBX 4,915 ($62.56) on Tuesday. Reckitt Benckiser Group has a 1 year low of GBX 4,034 ($51.35) and a 1 year high of GBX 5,418 ($68.97). The company has a debt-to-equity ratio of 110.26, a current ratio of 0.69 and a quick ratio of 0.46. The company has a market capitalization of £33.53 billion, a PE ratio of 22.49, a P/E/G ratio of 1.10 and a beta of 0.09. The company has a fifty day moving average of GBX 5,228.35 and a two-hundred day moving average of GBX 4,949.54.
Reckitt Benckiser Group (LON:RKT – Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported GBX 349.70 ($4.45) EPS for the quarter. Reckitt Benckiser Group had a return on equity of 18.70% and a net margin of 10.78%. As a group, analysts expect that Reckitt Benckiser Group will post 331.2110727 earnings per share for the current year.
Insider Activity at Reckitt Benckiser Group
Reckitt Benckiser Group Company Profile
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Recommended Stories
- Five stocks we like better than Reckitt Benckiser Group
- Following Congress Stock Trades
- Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Alibaba Caught in Tariff Crossfire: Is It Time to Buy?
- Investing in Travel Stocks Benefits
- Can Solid Biosciences Challenge Sarepta in the DMD Market?
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.